Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jane Griffiths

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

Novartis forms digital health investment company with Qualcomm

Expands work with Tricorder prize firm to develop 'beyond-the-pill' initiatives

- PMLiVE

Janssen partners with Isis on stomach conditions

Will develop treatments that target RNA in people with autoimmune disorders

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

The use of search engines in health

The vast majority of health seekers use search engines as a starting point to gain information on a disease or illness

UK unveils digital health strategy

Plans greater use of mobile technology and will track NHS 'digital health maturity'

- PMLiVE

Integrating digital: developing a social conference

Boehringer Ingelheim’s director of oncology Albert van Eijk on the digital elements of its multichannel efforts

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

- PMLiVE

Janssen’s blood cancer drug Imbruvica approved in Europe

European commission licenses the first-in-class drug for two rare diseases

- PMLiVE

Boehringer’s Ofev approved by FDA for rare lung disease

US regulator also gives the green light to Intermune's Esbriet

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links